Aclaris Therapeutics, Inc. (ACRS) Stock Price

ACRSStock

$6.01+226.63%52W

Market Cap$884.67M

P/E—

PEG Ratio—

Div yield—

Beta0.88

ACRS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)66.94%

Price vs S&P 500 (4W)7.14%

VGM Score41.78

Book Value / Share (Quarterly)$0.89

P/TBV (Annual)0.47x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-35.93%

Cash Flow / Share (Quarterly)$-0.44

Price vs S&P 500 (YTD)86.85%

Gross Margin (TTM)12.90%

Net Profit Margin (TTM)-921.50%

EPS (TTM)$-0.59

10-Day Avg Trading Volume1.79M

EPS Excl Extra (TTM)$-0.59

Revenue Growth (5Y)3.85%

EPS (Annual)$-0.53

ROI (Annual)-62.98%

Gross Margin (Annual)6.93%

Net Profit Margin (5Y Avg)-690.91%

Cash / Share (Quarterly)$0.65

Revenue Growth QoQ (YoY)-8.33%

ROA (Last FY)-40.46%

Revenue Growth TTM (YoY)-51.05%

EBITD / Share (TTM)$-0.66

ROE (5Y Avg)-58.84%

Operating Margin (TTM)-1050.16%

Cash Flow / Share (Annual)$-0.40

P/B Ratio7.12x

P/B Ratio (Quarterly)5.93x

Net Income / Employee (Annual)$-940,900

EV / Revenue (TTM)105.57x

ROA (TTM)-42.41%

EPS Incl Extra (Annual)$-0.53

Current Ratio (Annual)3.36x

Quick Ratio (Quarterly)3.46x

3-Month Avg Trading Volume1.71M

52-Week Price Return226.63%

Revenue / Employee (TTM)$119,100

Tangible BV / Share (Quarterly)$2.21

P/S Ratio (Annual)113.32x

Asset Turnover (Annual)0.05x

52-Week High$6.60

Operating Margin (5Y Avg)-734.98%

EPS Excl Extra (Annual)$-0.53

CapEx CAGR (5Y)15.97%

Tangible BV CAGR (5Y)-5.47%

26-Week Price Return78.87%

Quick Ratio (Annual)3.36x

13-Week Price Return31.51%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.46x

Enterprise Value$867.71M

Revenue / Share Growth (5Y)-15.95%

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)0.46%

Revenue / Employee (Annual)$113,400

Pretax Margin (Annual)-829.58%

Cash / Share (Annual)$0.75

3-Month Return Std Dev57.19%

Gross Margin (5Y Avg)31.55%

Net Income / Employee (TTM)$-1,097,700

ROE (Last FY)-62.98%

EPS Basic Excl Extra (Annual)$-0.53

Receivables Turnover (TTM)2.57x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.59

Receivables Turnover (Annual)2.66x

ROI (TTM)-61.65%

P/S Ratio (TTM)107.91x

Pretax Margin (5Y Avg)-691.15%

Revenue / Share (Annual)$0.06

Tangible BV / Share (Annual)$2.21

Price vs S&P 500 (52W)208.07%

Year-to-Date Return99.67%

5-Day Price Return-4.75%

EPS Normalized (Annual)$-0.53

ROA (5Y Avg)-43.11%

Net Profit Margin (Annual)-829.58%

Month-to-Date Return15.58%

Cash Flow / Share (TTM)$-1.65

EBITD / Share (Annual)$-0.62

Operating Margin (Annual)-975.91%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-58.84%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.59

P/TBV (Quarterly)0.47x

P/B Ratio (Annual)3.16x

Inventory Turnover (TTM)8.60x

Pretax Margin (TTM)-921.50%

Book Value / Share (Annual)$0.86

Price vs S&P 500 (13W)29.56%

Beta0.88x

Revenue / Share (TTM)$0.06

ROE (TTM)-61.65%

52-Week Low$1.74

vGradeF

gGradeD

mGradeB

vgmGradeC

ACRS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.16	-$0.15	+6.25%(+$0.01)
Q1 2026	May 7, 2026	-$0.16	-$0.15	+3.67%(+$0.01)
Q4 2025	Feb 26, 2026	-$0.14	-$0.16	-17.07%(-$0.02)
Q3 2025	Nov 6, 2025	-$0.14	-$0.12	+14.29%(+$0.02)
Q2 2025	Aug 7, 2025	-$0.13	-$0.13	-1.30%(-$0.00)

ACRS Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.31

4.35

4.33

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
ACRSAclaris Therapeutics, Inc.	F	D	B	$6.01
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing immuno-inflammatory disease therapies, including candidates Zunsemetinib (an Oral MK2 Inhibitor), Lepzacitinib, ATI-2138 (an ITJ Inhibitor), and ATI-052. The company also operates a contract research segment providing laboratory services, though therapeutics drives the majority of revenue.